Results 71 to 80 of about 216,694 (240)

Timing of high-efficacy therapy in relapsing-remitting multiple sclerosis: A systematic review.

open access: yesAutoimmunity Reviews, 2017
BACKGROUND Immunotherapy initiated early after first presentation of relapsing-remitting multiple sclerosis is associated with improved long-term outcomes.
B. Merkel   +4 more
semanticscholar   +1 more source

The Lupus Damage Index Revision Program: Results From the Item Generation and Reduction Phases

open access: yesArthritis Care &Research, EarlyView.
Objective A data‐driven and expert/patient consensus‐based project to develop a revised Systemic Lupus International Collaborating Clinics (SLICC)/American College of Rheumatology (ACR) Damage Index (SDI) is under way supported by SLICC, ACR, and the Lupus Foundation of America. Our objective is to report the item generation and reduction phase results
Burak Kundakci   +25 more
wiley   +1 more source

Autoantigen mRNA‐LNP Vaccination Drives Therapeutic Efficacy in Preclinical Models for Autoimmunity

open access: yesAdvanced Science, EarlyView.
Systemic and intramuscular delivery of autoantigen mRNA via lipid nanoparticles reprograms antigen‐presenting cells toward a mature, homeostatic state, driving antigen‐specific T cell exhaustion and providing therapeutic efficacy across autoimmune disease models.
Paulien Baeten   +30 more
wiley   +1 more source

Role of oral teriflunomide in the management of multiple sclerosis

open access: yesNeuropsychiatric Disease and Treatment, 2013
Radu Tanasescu,1,2 Nikos Evangelou,1 Cris S Constantinescu1 1Academic Division of Clinical Neurology, University of Nottingham, Nottingham, UK; 2Department of Neurology, Colentina Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest ...
Tanasescu R   +2 more
doaj  

POEMS Syndrome: 2026 Update on Diagnosis, Risk‐Stratification, and Management

open access: yesAmerican Journal of Hematology, EarlyView.
ABSTRACT Disease Overview POEMS syndrome is a life‐threatening syndrome due to an underlying plasma cell neoplasm. The major criteria for the syndrome are polyneuropathy, clonal plasma cell disorder (PCD), sclerotic bone lesions, elevated vascular endothelial growth factor, and the presence of Castleman disease.
Angela Dispenzieri
wiley   +1 more source

Two decades of subcutaneous glatiramer acetate injection: current role of the standard dose, and new high-dose low-frequency glatiramer acetate in relapsing–remitting multiple sclerosis treatment

open access: yesPatient Preference and Adherence, 2014
Matteo Caporro, Giulio Disanto, Claudio Gobbi, Chiara Zecca Neurocenter of Southern Switzerland, Ospedale Regionale di Lugano, Lugano, Switzerland Abstract: Glatiramer acetate, a synthetic amino acid polymer analog of myelin basic protein, is one of ...
Caporro M, Disanto G, Gobbi C, Zecca C
doaj  

The Neutrophil-to-Lymphocyte Ratio is Related to Disease Activity in Relapsing Remitting Multiple Sclerosis

open access: yesCells, 2019
Background: The role of the neutrophil-to-lymphocyte ratio (NLR) of peripheral blood has been investigated in relation to several autoimmune diseases.
E. D’Amico   +5 more
semanticscholar   +1 more source

Chronic Rhinosinusitis and Nasal Polyps in Eosinophilic Granulomatosis With Polyangiitis: A Scoping Review

open access: yesInternational Forum of Allergy &Rhinology, EarlyView.
ABSTRACT Background Chronic rhinosinusitis (CRS) is one of the most common manifestations of eosinophilic granulomatosis with polyangiitis (EGPA), often preceding the diagnosis of systemic vasculitis by several years. The sinonasal presentation of EGPA typically resembles CRS with nasal polyps (CRSwNP), making it clinically indistinguishable from those
Alisha Sharma   +12 more
wiley   +1 more source

Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis

open access: yesNeurology, 2018
Objective To assess dose-response effects of the anti-CD20 monoclonal antibody ofatumumab on efficacy and safety outcomes in a phase 2b double-blind study of relapsing forms of multiple sclerosis (RMS).
A. Bar-Or   +10 more
semanticscholar   +1 more source

From Marginal to Central: Marginal Zone‐like B Cells as Critical Targets in Cladribine‐Treated Multiple Sclerosis

open access: yesAnnals of Neurology, EarlyView.
Objective Multiple sclerosis (MS) is a chronic autoimmune disease where B cells play a central pathogenic role. Cladribine, an oral therapy, provides durable benefits by reshaping lymphocyte populations, yet its specific long‐term impact on distinct B‐cell subsets is not fully understood.
Marta Pirronello   +20 more
wiley   +1 more source

Home - About - Disclaimer - Privacy